ReviewCold Spring Harbor perspectives in medicine2014
Therapeutic and prophylactic applications of bacteriophage components in modern medicine.
Review in Cold Spring Harbor perspectives in medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03231267 (Existence in the Human Digestive Flora of Phages Able to Prevent the Acquisition of Multiresistant Enterobacteria), which is not on this map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Existence in the Human Digestive Flora of Phages Able to Prevent the Acquisition of Multiresistant Enterobacteria: PHAGO- BMR
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Reassessment of Historical Clinical Trials Supports the Effectiveness of Phage Therapy.Clinical microbiology reviews · 2022Pooled it
- Preclinical Evaluation of a Phage T4-Based Multi-Epitope Nanoparticle Vaccine Against Porcine Epidemic Diarrhea Virus.Transboundary and emerging diseases · 2026Article
- Bacteriophage therapy beyond antibiotics: emerging innovations for infectious and non-infectious diseases.Frontiers in cellular and infection microbiology · 2026Review
- A review on phytochemical and bacteriophage based therapeutic strategies for the management of Brucellosis.Frontiers in veterinary science · 2026Review
- Cytokines Meet Phages: A Revolutionary Pathway to Modulating Immunity and Microbial Balance.Biomedicines · 2025Review
- Bacteriophage vB_SepP_134 and Endolysin LysSte_134_1 as Potential Staphylococcus-Biofilm-Removing Biological Agents.Viruses · 2024Article
- Review
- Review
- Review
- Article
- Bacteriophages as Biotechnological Tools.Viruses · 2023Review
- Article
- Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.Journal of experimental & clinical cancer research : CR · 2022Article
- Treating bacterial infections with bacteriophages in the 21st century.Southern African journal of infectious diseases · 2022Article
- Phage Therapy: A Different Approach to Fight Bacterial Infections.Biologics : targets & therapy · 2022Review
- Intestinal virome and therapeutic potential of bacteriophages in liver disease.Journal of hepatology · 2021Review
- Phage therapeutics: from promises to practices and prospectives.Applied microbiology and biotechnology · 2021Review
- Evaluation of the Immune Response of a Candidate Phage-Based Vaccine againstPharmaceutics · 2021Article
- Solvent Extraction ofPHAGE (New Rochelle, N.Y.) · 2021Article
- Bacteriophages as Potential Tools for Use in Antimicrobial Therapy and Vaccine Development.Pharmaceuticals (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
As the interactions of phage with mammalian innate and adaptive immune systems are better delineated and with our ability to recognize and eliminate toxins and other potentially harmful phage gene products, the potential of phage therapies is now being realized. Early efforts to use phage therapeutically were hampered by inadequate phage purification and limited knowledge of phage-bacterial and phage-human relations. However, although use of phage as an antibacterial therapy in countries that require controlled clinical studies has been hampered by the high costs of patient trials, their use as vaccines and the use of phage components such as lysolytic enzymes or lysozymes has progressed to the point of commercial applications. Recent studies concerning the intimate associations between mammalian hosts and bacterial and phage microbiomes should hasten this progress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.